我们先从一家名为 Obsidian Therapeutics 的小型临床阶段生物技术公司说起,股票代码为 OBX。根据文件,Google 以约1,680万美元的投资将其纳入了自己的投资组合。
We begin with a small clinical-stage biotechnology company called Obsidian Therapeutics, ticker symbol OBX, which Google, according to documents, has added to its investment portfolio with an investment of approximately $16.8 million.
需要说明的是,这并不是 Google 突然决定在便宜的生物科技股上大肆挥霍。Obsidian 于8月通过与一家名为 Galera Therapeutics 的陷入困境的生物技术公司反向合并而上市,Google 的早期投资部门曾对后者进行过私募投资。这家公司的股份现已转换为公开股份。
To clarify, this is not a sudden decision by Google to day-splurge on cheap biotech stocks. Obsidian went public in August through a reverse merger with a struggling biotech company called Galera Therapeutics, in which Google’s early investment arm had a private investment.
That company whose shares have now been converted to public shares.